Clinical Trial Update: Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients [Phase 3]

View source ↗

Summary

Phase 3 esophageal pH study of compound sodium alginate oral suspension in GERD has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Compound Sodium Alginate Oral Suspension Sachet (sodium alginate)

Snippet

Sponsor: Reckitt Benckiser Healthcare (UK) Limited | Conditions: Gastro-esophageal Reflux Disease (GERD) | Phase 3 | Status: TERMINATED